Large Cell Neuroendocrine Carcinoma

Textbook of Uncommon Cancer, Third Edition

Volumn , Issue , 2006, Pages 298-306

  Travis, William D ^a   Krug, Lee M ^a   Rusch, Valerie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Atypical carcinoid; Chemotherapy; Large cell neuroendocrine carcinoma; Radiation therapy; Small cell carcinoma; Surgery; Typical carcinoid

Indexed keywords

EID: 70349288097     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470030542.ch25     Document Type: Chapter

References (72)

1. Travis WD, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15: 529-53.
2. Travis WD, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
3. Travis WD, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22: 934-44.
4. Travis WD, et al. Collaboration with L.H. Sobin and pathologists from 14 countries. Histological Typing of Lung and Pleural Tumors. Berlin, Germany: Springer-Verlag, 1999.
5. Battafarano RJ, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130: 166-72.
6. Dresler CM, et al. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 1997; 63: 180-5.
7. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996; 62: 798-809.
8. Zacharias J, et al. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg 2003; 75: 348-52.
9. Jiang SX, et al. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998; 22: 526-37.
10. Garcia-Yuste M, et al. Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Ann Thorac Surg 2000; 70: 258-63.
11. Iyoda A, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001; 91: 1992-2000.
12. Mazieres J, et al. Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases. Lung Cancer 2002; 37: 287-92.
13. Takei H, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002; 124: 285-92.
14. Hage R, et al. Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg 2003; 23: 457-60.
15. Kakinuma H, et al. Diagnostic findings of bronchial brush cytology for pulmonary large cell neuroendocrine carcinomas: comparison with poorly differentiated adenocarcinomas, squamous cell carcinomas, and small cell carcinomas. Cancer 2003; 99: 247-54.
16. Ab' Saber AM, et al. Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas. Ann Thorac Surg 2004; 77: 1883-90.
17. Casali C, et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 2004; 77: 247-52.
18. Daddi N, et al. Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg 2004; 26: 813-7.
19. Doddoli C, et al. Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery. Ann Thorac Surg 2004; 77: 1168-72.
20. Oshiro Y, et al. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. AJR Am J Roentgenol 2004; 182: 87-91.
21. Paci M, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004; 77: 1163-7.
22. Filosso PL, et al. Large-cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide. J Thorac Cardiovasc Surg 2005; 129: 819-24.
23. Kozuki T, et al. Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol 2005; 131: 147-51.
24. Rossi G, et al. The role of chemotherapy and receptor tyrosine kinases KIT, PDGFR-alpha, PDGFR-beta, and Met in large cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005; 23: 8774-85.
25. Iyoda A, et al. Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann Thorac Surg 2002; 73: 1049-54.
26. Onuki N, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999; 85: 600-7.
27. Brambilla E, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996; 149: 1941-52.
28. Hiroshima K, et al. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer 2004; 100: 1190-8.
29. Iyoda A, et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg 2004; 77: 1891-5.
30. Jiang SX, et al. The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung. Mod Pathol 1999; 12: 362-9.
31. Przygodzki RM, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996; 148: 1531-41.
32. Sampietro G, et al. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis. Appl Immunohistochem Mol Morphol 2000; 8: 49-56.
33. Hollstein M, et al. p53 mutations in human cancers. Science 1991; 253: 49-53.
34. Beasley MB, et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003; 34: 136-42.
35. Igarashi T, et al. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol 2004; 17: 1259-67.
36. Kobayashi Y, et al. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors. Cancer Sci 2004; 95: 334-41.
37. Araki K, et al. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003; 40: 173-80.
38. Pelosi G, et al. CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch 2004; 445: 449-55.
39. Debelenko LV, et al. MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. Genes Chromosomes Cancer 2000; 28: 58-65.
40. Rossi G, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004; 122: 884-93.
41. Sturm N, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001; 32: 918-25.
42. Lantuejoul S, et al. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol 1998; 22: 1267-76.
43. Folpe AL, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999; 12: 5-8.
44. Sturm N, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002; 33: 175-82.
45. Said JW, et al. Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors. Hum Pathol 1985; 16: 236-40.
46. Hiroshima K, et al. Cytological characteristics of pulmonary large cell neuroendocrine carcinoma. Lung Cancer 2005; 48: 331-7.
47. Iyoda A, et al. Imprint cytologic features of pulmonary large cell neuroendocrine carcinoma: Comparison with classic large cell carcinoma. Oncol Rep 2004; 11: 285-8.
48. Nicholson SA, Ryan MR. A review of cytologic findings in neuroendocrine carcinomas including carcinoid tumors with histologic correlation. Cancer 2000; 90: 148-61.
49. Wiatrowska BA, Krol J, Zakowski MF. Large-cell neuroendocrine carcinoma of the lung: proposed criteria for cytologic diagnosis. Diagn Cytopathol 2001; 24: 58-64.
50. Yang YJ, et al. Diagnosis of high-grade pulmonary neuroendocrine carcinoma by fine-needle aspiration biopsy: nonsmall-cell or small-cell type? Diagn Cytopathol 2001; 25: 292-300.
51. Travis WD, et al. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998; 29: 272-9.
52. Howe MC, et al. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 2005; 46: 195-201.
53. Hiroshima K, et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg 2002; 73: 1732-5.
54. Carnaghi C, et al. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. Ann Oncol 2001; 12(Suppl 2): S119-23.
55. Baldi A, et al. Neuroendocrine differentiation in non-small cell lung carcinomas. In Vivo 2000; 14: 109-14.
56. Abbona G, et al. Chromogranin A gene expression in non-small cell lung carcinomas. J Pathol 1998; 186: 151-6.
57. Hage R, et al. Neural cell adhesion molecule expression: prognosis in 889 patients with resected non-small cell lung cancer. Chest 1998; 114: 1316-20.
58. Kwa HB, et al. Prognostic factors in resected non-small cell lung cancer: an immunohistochemical study of 39 cases. Lung Cancer 1996; 16: 35-45.
59. Schleusener JT, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 1996; 77: 1284-91.
60. Senderovitz T, Skov BG, Hirsch FR. Neuroendocrine characteristics in malignant lung tumors: implications for diagnosis, treatment, and prognosis. Cancer Treat Res 1995; 72: 143-54.
61. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 1994; 106: 367S-371S.
62. Carles J, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993; 10: 209-19.
63. Pujol JL, et al. Neural cell adhesion molecule and prognosis of surgically resected lung cancer. Am Rev Respir Dis 1993; 148: 1071-5.
64. Skov BG, et al. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 1991; 2: 355-60.
65. Sundaresan V, et al. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br. J Cancer 1991; 64: 333-8.
66. Berendsen HH, et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989; 7: 1614-20.
67. Jung KJ, et al. Large cell neuroendocrine carcinoma of the lung: clinical, CT, and pathologic findings in 11 patients. J Thorac Imaging 2001; 16: 156-62.
68. Shin AR, et al. Large cell neuroendocrine carcinoma of the lung: radiologic and pathologic findings. J Comput Assist Tomogr 2000; 24: 567-73.
69. Murren J, Glatstein E, Pass HI. Small cell lung cancer. In DeVita VT, Hellman S, Rosenberg SA. (eds) Cancer, Principles and Practice of Oncology. Philadelphia, Pennsylvania: Lippincott, Williams & Wilkins, 2001: 983-1018.
70. Arriagada R, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60.
71. Winton T, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97.
72. Iyoda A, et al. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer 2001; 92: 1108-12.